A systematic review on the epidemiology of RPE65 mutations reported in the literature showed that there were significant variations of RPE65 proportions within countries as… Read More »A systematic literature review on the epidemiology of RPE65 mutations report significant variations in the literature within countries as well as regions.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the January 8th, 2023 edition of EURETINA’s web-based digital magazine, “EURETINA Brief”. EURETINA… Read More »January 8th, 2023 “EURETINA-Brief”© Issue No. 264
Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced the FDA clearance of its Investigational New Drug (IND)… Read More »Opus Genetics Inc., has announced an IND application for “OPGx-001” for the treatment of LCA5 retinal disease
An interim analysis from a Phase II study for a novel peptide (THR-149) is aimed to prevent the induction of retinal vascular permeability, neurodegeneration and… Read More »Phase II data on a novel peptide candidate – plasma kallikrein (PKal) (THR-149) – for treatment of diabetic macular edema (DME)
Researchers at the Birmingham and Midland Eye Centre, UK, has reported five-years’ of real-world results from the application of the fluocinolone acetonide implant (ILUVIEN), for… Read More »Five-year real-world results on intravitreal fluocinolone treatment of chronic diabetic macular oedema (DMO) has shown improved or stabilised VA
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 17th, 2022 edition of EURETINA’s web-based… Read More »December 17th, 2022 “EURETINA-Brief”© Issue No. 263
IVERIC bio, Inc., (NASDAQ: ISEE), based in Parsippany New Jersey, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for… Read More »Avacincaptad pegol (ACP, “Zimura”) for geographic atrophy (IVERIC bio, Inc., NASDAQ: ISEE)) has announced a Breakthrough Therapy Designation from the FDA
Despite positive initial clinical data from an ongoing open label Phase I/II “BRILLIANCE” study, named EDIT-101, a CRISPR-based experimental treatment for the treatment of Leber… Read More »Pausing of CRISPR gene editing therapy for LCA CEP290-related retinal degeneration from >15 patients
In a recent study, patient preferences in the management of wet age-related macular degeneration (AMD) have reported several treatment attributes using patient-centred methods. Patients with… Read More »Patient preferences in the management of wet AMD shows harmonization of outcomes across geographies
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the November 28th, 2022 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »November 28th, 2022 “EURETINA-Brief”© Issue No. 262